A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine

Edward E Walsh, Ann R Falsey, Daniel A Scott, Alejandra Gurtman, Agnieszka M Zareba, Kathrin U Jansen, William C Gruber, Philip R Dormitzer, Kena A Swanson, David Radley, Emily Gomme, David Cooper, Beate Schmoele-Thoma, Edward E Walsh, Ann R Falsey, Daniel A Scott, Alejandra Gurtman, Agnieszka M Zareba, Kathrin U Jansen, William C Gruber, Philip R Dormitzer, Kena A Swanson, David Radley, Emily Gomme, David Cooper, Beate Schmoele-Thoma

Abstract

Background: Protection against human respiratory syncytial virus (RSV) remains an unmet need potentially addressable by maternal immunization. This phase 1/2 study evaluated a bivalent prefusion F vaccine (RSVpreF) with antigens from RSV subgroups A and B.

Methods: Adults 18-49 years old (N = 618) were randomized to receive placebo or 60, 120, or 240 µg RSVpreF with or without Al(OH)3. Safety and immunogenicity were evaluated.

Results: RSVpreF recipients more frequently reported local reactions and systemic events than placebo recipients; these were mostly mild or moderate. No vaccine-related serious adverse events occurred through 12 months postvaccination. All RSVpreF formulations induced 1-month postvaccination virus-neutralizing titers higher than those associated with protection of high-risk infants by palivizumab, the only prophylactic currently available for RSV. Geometric mean fold rises (GMFRs) across RSVpreF doses/formulations were 10.6-16.9 for RSV A and 10.3-19.8 for RSV B at 1 month postvaccination, greater than those historically elicited by postfusion F vaccines. GMFRs were 3.9-5.2 and 3.7-5.1, respectively, at 12 months postvaccination.

Conclusions: RSVpreF formulations were safe, well tolerated, and induced robust neutralizing responses in adults. These findings support development of RSVpreF, which is being evaluated in a pivotal phase 3 study for maternal immunization.

Clinical trials registration: NCT03529773.

Keywords: F protein; immunogenicity; maternal vaccination; neutralizing responses; respiratory syncytial virus; safety; vaccine.

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Study design. Expanded cohort groups included in this report are highlighted in yellow. Abbreviations: RSVpreF, bivalent respiratory syncytial virus prefusion F vaccine; SIIV, seasonal inactivated influenza vaccine.
Figure 2.
Figure 2.
Disposition of participants 18–49 years old in the (A) sentinel and (B) expanded cohorts. Expanded cohort groups included in this report are highlighted in yellow. Participants who did not receive SIIV concomitantly with the RSV vaccine received it 1 month later. Abbreviations: Cmplt’d, completed; f/u, follow-up; PV1, postvaccination 1; rec’d, received; RSV, respiratory syncytial virus; RSVpreF, bivalent RSV prefusion F vaccine; SIIV, seasonal inactivated influenza vaccine.
Figure 3.
Figure 3.
Percentages of participants 18–49 years old in the sentinel and expanded cohorts combined reporting individual (A) local reactions or (B) systemic events by severity within 14 days postvaccination 1. Total number of participants (n) = 52–54 per group. Abbreviations: 60, 60 µg RSVpreF; 60A, 60 µg RSVpreF + AI(OH)3; 120, 120 µg RSVpreF; 120A, 120 µg RSVpreF + AI(OH)3; 240, 240 µg RSVpreF; 240A, 240 µg RSVpreF + AI(OH)3; P, placebo; RSVpreF, bivalent respiratory syncytial virus prefusion F vaccine.
Figure 4.
Figure 4.
RSV neutralizing GMTs through 12 months postvaccination 1 and corresponding GMFRs compared with baseline for (A) RSV subgroup A and (B) RSV subgroup B in participants 18–49 years old in the sentinel and expanded cohorts combined. Data are shown separately by dose level for ease of viewing. Abbreviations: GMFR, geometric mean fold rise; GMT, geometric mean titer; RSV, respiratory syncytial virus; RSVpreF, bivalent RSV prefusion F vaccine.
Figure 5.
Figure 5.
Vaccine-elicited RSV A/B neutralizing titer fold rise as a function of prevaccination RSV A/B neutralizing titers. For each individual, the prevaccination titer is the combined A/B 50% neutralizing titer, calculated as the geometric mean of the RSV A and B neutralizing titers. The combined A/B 50% neutralizing titer fold rise is the geometric mean of the fold rises of 50% neutralizing titers against RSV A and RSV B from prevaccination to 1 month postvaccination. The correlation across all data was calculated at −0.61. Data are shown for participants 18–49 years old in the sentinel and expanded cohorts combined. Abbreviations: GMFR, geometric mean fold rise; RSV, respiratory syncytial virus; RSVpreF, bivalent RSV prefusion F vaccine.

References

    1. Hall CB, Simoes EAF, Anderson LJ.. Clinical and epidemiologic features of respiratory syncytial virus. In: Anderson LJ, Graham BS, eds. Challenges and opportunities for respiratory syncytial virus vaccines. Berlin, Heidelberg: Springer, 2013:39–57.
    1. Glezen WP, Taber LH, Frank AL, Kasel JA.. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140:543–6.
    1. Murray J, Bottle A, Sharland M, et al. . Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS One 2014; 9:e89186.
    1. Rha B, Curns AT, Lively JY, et al. . Respiratory syncytial virus-associated hospitalizations among young children: 2015–2016. Pediatrics 2020; 146:e20193611.
    1. Boyoglu-Barnum S, Chirkova T, Anderson LJ.. Biology of infection and disease pathogenesis to guide RSV vaccine development. Front Immunol 2019; 10:1675.
    1. Johnson S, Oliver C, Prince GA, et al. . Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176:1215–24.
    1. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531–7.
    1. Meissner HC, Kimberlin DW.. RSV immunoprophylaxis: does the benefit justify the cost? Pediatrics 2013; 132:915–8.
    1. AAP Committee on Infectious Diseases. Red Book® 2018-2021. 31st ed. Itasca, IL: American Academy of Pediatrics, 2018.
    1. Kim HW, Canchola JG, Brandt CD, et al. . Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422–34.
    1. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE.. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405–21.
    1. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G.. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435–48.
    1. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH.. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969; 89:449–63.
    1. Domachowske JB, Rosenberg HF.. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev 1999; 12:298–309.
    1. Waris ME, Tsou C, Erdman DD, Day DB, Anderson LJ.. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol 1997; 71:6935–9.
    1. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL.. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98:708–15.
    1. Ochola R, Sande C, Fegan G, et al. . The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One 2009; 4:e8088.
    1. Chu HY, Steinhoff MC, Magaret A, et al. . Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh. J Infect Dis 2014; 210:1582–9.
    1. Madhi SA, Polack FP, Piedra PA, et al. . Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med 2020; 383:426–39.
    1. Munoz FM, Swamy GK, Hickman SP, et al. . Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis 2019; 220:1802–15.
    1. Aranda SS, Polack FP.. Prevention of pediatric respiratory syncytial virus lower respiratory tract illness: perspectives for the next decade. Front Immunol 2019; 10:1006.
    1. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013; 62:131–5.
    1. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB.. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2018-19 influenza season. MMWR Recomm Rep 2018; 67:1–20.
    1. Baxter R, Bartlett J, Fireman B, Lewis E, Klein NP.. Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics 2017; 139:e20164091.
    1. Singh A, Pallikadavath S, Ogollah R, Stones W.. Maternal tetanus toxoid vaccination and neonatal mortality in rural north India. PLoS One 2012; 7:e48891.
    1. Levine S, Klaiber-Franco R, Paradiso PR.. Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol 1987; 68:2521–4.
    1. Wertz GW, Collins PL, Huang Y, Gruber C, Levine S, Ball LA.. Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci USA 1985; 82:4075–9.
    1. McLellan JS, Chen M, Leung S, et al. . Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013; 340:1113–7.
    1. Johnson PR, Spriggs MK, Olmsted RA, Collins PL.. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci USA 1987; 84:5625–9.
    1. Johnson PR, Collins PL.. The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness. J Gen Virol 1988; 69:2623–8.
    1. Hause AM, Henke DM, Avadhanula V, Shaw CA, Tapia LI, Piedra PA.. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS One 2017; 12:e0175792.
    1. Calder LJ, Gonzalez-Reyes L, Garcia-Barreno B, et al. . Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 2000; 271:122–31.
    1. Smith BJ, Lawrence MC, Colman PM.. Modelling the structure of the fusion protein from human respiratory syncytial virus. Protein Eng 2002; 15:365–71.
    1. McLellan JS, Chen M, Joyce MG, et al. . Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342:592–8.
    1. Crank MC, Ruckwardt TJ, Chen M, et al. . A proof of concept for structure-based vaccine design targeting RSV in humans. Science 2019; 365:505–9.
    1. McLellan JS. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol 2015; 11:70–5.
    1. Falloon J, Yu J, Esser MT, et al. . An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults. J Infect Dis 2017; 216:1362–70.
    1. Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants. Hum Vaccin Immunother 2014; 10:2789–94.
    1. McDonald JU, Rigsby P, Dougall T, Engelhardt OG, Study Participants. Establishment of the first WHO international standard for antiserum to respiratory syncytial virus: report of an international collaborative study. Vaccine 2018; 36:7641–9.
    1. McDonald JU, Rigsby P, Atkinson E, Engelhardt OG, Study Participants. Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: an international collaborative study. Vaccine 2020; 38:800–7.
    1. Griffin MP, Yuan Y, Takas T, et al. . Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020; 383:415–25.
    1. Hall CB, Walsh EE, Schnabel KC, et al. . Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990; 162:1283–90.
    1. Parikh RC, McLaurin KK, Margulis AV, et al. . Chronologic age at hospitalization for respiratory syncytial virus among preterm and term infants in the United States. Infect Dis Ther 2017; 6:477–86.
    1. Hall CB, Long CE, Schnabel KC.. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001; 33:792–6.
    1. Sarvas H, Seppala I, Kurikka S, Siegberg R, Makela O.. Half-life of the maternal IgG1 allotype in infants. J Clin Immunol 1993; 13:145–51.
    1. Langley JM, Sales V, McGeer A, et al. . A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age. Vaccine 2009; 27:5913–9.
    1. Flanagan KL, Fink AL, Plebanski M, Klein SL.. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol 2017; 33:577–99.
    1. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M.. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012:985646.
    1. Glenn GM, Fries LF, Thomas DN, et al. . A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 2016; 213:411–22.
    1. Peterson JT, Zareba AM, Fitz-Patrick D, et al. . Safety and immunogenicity of a respiratory syncytial virus prefusion F vaccine when co-administered with a tetanus, diphtheria, and acellular pertussis vaccine [published online ahead of print 12 October 2021]. J Infect Dis doi: 10.1093/infdis/jiab505.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa